SCHEMBL3755519

SCHEMBL3755519

[C]1=C2C=CC=CC2Oc2ccccc21

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5342826 0.64 P2RY6 (0.33)
SCHEMBL14304447 0.63 CYP1A2 (0.33)
SCHEMBL5139861 0.62 MAOB (0.32)
SCHEMBL2102618 0.62
SCHEMBL1533620 0.61
SCHEMBL19205924 0.59
SCHEMBL6410680 0.58 KDM4E (0.32)
SCHEMBL13138773 0.58 ABCG2 (0.39)
SCHEMBL5093557 0.57
SCHEMBL600651 0.57 KDM4E (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020137794-A1 Retinoic acid receptor (RAR) agonists, agonists for steroid/thyroid hormone receptor superfamily, and an agonist for a heterodimer partner SALK INSTITUTE FOR BIOLOGICAL STUDIES, THE 2002-09-26 US claimed
US-6436993-B1 SYNERGISTIC MIXTURES OF RETINOIC ACID RECEPTOR (RAR) ANTAGONISTS AND STEROID, THYROID OR RETINOID RECEPTOR AGONISTS SUCH AS PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS USED TO CONTROL CELLULAR PROCESSES THE SALK INSTITUTE FOR BIOLOGICAL STUDIES 2002-08-20 US claimed
WO-2001003659-A1 USE OF RAR ANTAGONISTS AS MODULATORS OF HORMONE MEDIATED PROCESSES THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2001-01-18 WO claimed
EP-3760193-B9 INTRACELLULAR DELIVERY VEHICLE KIRIN HOLDINGS KK (JP) 2023-11-01 EP disclosed
CN-113214422-B intracellular delivery vehicles 麒麟控股株式会社 2023-10-10 CN disclosed
EP-3760193-B1 INTRACELLULAR DELIVERY VEHICLE KIRIN HOLDINGS KK (JP) 2023-07-05 EP disclosed
US-11649311-B2 Temperature-sensitive fluorescent probe for introduction into cell KIRIN HOLDINGS KABUSHIKI KAISHA (JP) 2023-05-16 US disclosed
US-11524947-B2 Organic compound, light emitting diode and light emitting device having the compound LG DISPLAY CO., LTD. (KR) 2022-12-13 US disclosed
US-11199537-B2 Temperature-sensitive fluorescent probe for introduction into cell KIRIN HOLDINGS KABUSHIKI KAISHA (JP) 2021-12-14 US disclosed
EP-3760193-A1 INTRACELLULAR DELIVERY VEHICLE Kirin Holdings Kabushiki Kaisha (JP) 2021-01-06 EP disclosed
US-20200309782-A1 INTRACELLULAR DELIVERY VEHICLE KIRIN HOLDINGS KABUSHIKI KAISHA (JP) 2020-10-01 US disclosed
US-20070202101-A1 Combination therapy using anti-EGFR antibodies and anti-hormonal agents MERCK PATENT GMBH (DE) 2007-08-30 US disclosed
WO-2005120583-A2 METHOD FOR PREVENTING OR TREATING CARDIAC HYPERTROPHY WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2005-12-22 WO disclosed
US-20050276804-A1 Method for preventing or treating cardiac hypertrophy WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2005-12-15 US disclosed
US-20040131611-A1 Combination therapy using anti-egfr antibodies and anti-hormonal agents MERCK PATENT GMBH (DE) 2004-07-08 US disclosed
EP-1385546-A1 COMBINATION THERAPY USING ANTI-EGFR ANTIBODIES AND ANTI-HORMONAL AGENTS MERCK PATENT GmbH (DE) 2004-02-04 EP disclosed
WO-2002089842-A1 COMBINATION THERAPY USING ANTI-EGFR ANTIBODIES AND ANTI-HORMONAL AGENTS MERCK PATENT GMBH (DE) 2002-11-14 WO disclosed
US-20020137794-A1 Retinoic acid receptor (RAR) agonists, agonists for steroid/thyroid hormone receptor superfamily, and an agonist for a heterodimer partner SALK INSTITUTE FOR BIOLOGICAL STUDIES, THE 2002-09-26 US disclosed
US-6436993-B1 SYNERGISTIC MIXTURES OF RETINOIC ACID RECEPTOR (RAR) ANTAGONISTS AND STEROID, THYROID OR RETINOID RECEPTOR AGONISTS SUCH AS PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS USED TO CONTROL CELLULAR PROCESSES THE SALK INSTITUTE FOR BIOLOGICAL STUDIES 2002-08-20 US disclosed
WO-2001003659-A1 USE OF RAR ANTAGONISTS AS MODULATORS OF HORMONE MEDIATED PROCESSES THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2001-01-18 WO disclosed